164 related articles for article (PubMed ID: 31837035)
1. A risk prediction model for heart failure hospitalization in type 2 diabetes mellitus.
Williams BA; Geba D; Cordova JM; Shetty SS
Clin Cardiol; 2020 Mar; 43(3):275-283. PubMed ID: 31837035
[TBL] [Abstract][Full Text] [Related]
2. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
Berg DD; Wiviott SD; Scirica BM; Gurmu Y; Mosenzon O; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Johansson PA; Langkilde AM; Raz I; Braunwald E; Sabatine MS
Circulation; 2019 Nov; 140(19):1569-1577. PubMed ID: 31474116
[TBL] [Abstract][Full Text] [Related]
3. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.
Pratley RE; Husain M; Lingvay I; Pieber TR; Mark T; Saevereid HA; Møller DV; Zinman B;
Cardiovasc Diabetol; 2019 Nov; 18(1):156. PubMed ID: 31729990
[TBL] [Abstract][Full Text] [Related]
4. Sulphonylureas monotherapy and risk of hospitalization for heart failure in patients with type 2 diabetes mellitus: A population-based cohort study in China.
Xu Y; Wang T; Yang Z; Lin H; Shen P; Zhan S
Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):635-643. PubMed ID: 32383226
[TBL] [Abstract][Full Text] [Related]
5. Predicting incident heart failure among patients with type 2 diabetes mellitus: The DM-CURE risk score.
Lin Y; Shao H; Shi L; Anderson AH; Fonseca V
Diabetes Obes Metab; 2022 Nov; 24(11):2203-2211. PubMed ID: 35801340
[TBL] [Abstract][Full Text] [Related]
6. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
[TBL] [Abstract][Full Text] [Related]
7. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
Fudim M; White J; Pagidipati NJ; Lokhnygina Y; Wainstein J; Murin J; Iqbal N; Öhman P; Lopes RD; Reicher B; Holman RR; Hernandez AF; Mentz RJ
Circulation; 2019 Nov; 140(20):1613-1622. PubMed ID: 31542942
[TBL] [Abstract][Full Text] [Related]
8. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
[TBL] [Abstract][Full Text] [Related]
9. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
McGuire DK; Van de Werf F; Armstrong PW; Standl E; Koglin J; Green JB; Bethel MA; Cornel JH; Lopes RD; Halvorsen S; Ambrosio G; Buse JB; Josse RG; Lachin JM; Pencina MJ; Garg J; Lokhnygina Y; Holman RR; Peterson ED;
JAMA Cardiol; 2016 May; 1(2):126-35. PubMed ID: 27437883
[TBL] [Abstract][Full Text] [Related]
10. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes.
Berg DD; Wiviott SD; Scirica BM; Zelniker TA; Goodrich EL; Jarolim P; Mosenzon O; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Langkilde AM; Raz I; Braunwald E; Sabatine MS; Morrow DA
Diabetes Care; 2021 Nov; 44(11):2573-2581. PubMed ID: 34535469
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of hospitalization risk for incident heart failure in non-Hispanic Black versus non-Hispanic White individuals with type 2 diabetes on empagliflozin (Empa-AA): Insights from real-world data.
Mishriky BM; Cummings DM; Fu Y; Halladay JR; Jones S; Boan AD; Jones S; Patil SP; Powell JR; Adams A; Irish W
Diabetes Obes Metab; 2024 May; 26(5):1830-1836. PubMed ID: 38361455
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P-TIMI 50 trial.
Freedman BL; Berg DD; Scirica BM; Bohula EA; Goodrich EL; Sabatine MS; Morrow DA; Bonaca MP
Clin Cardiol; 2022 Aug; 45(8):831-838. PubMed ID: 35855557
[TBL] [Abstract][Full Text] [Related]
13. Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry.
Fadini GP; Saragoni S; Russo P; Degli Esposti L; Vigili de Kreutzenberg S; Melazzini M; Avogaro A;
Diabetes Obes Metab; 2017 Oct; 19(10):1416-1424. PubMed ID: 28432754
[TBL] [Abstract][Full Text] [Related]
14. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
Huang TL; Hsiao FY; Chiang CK; Shen LJ; Huang CF
PLoS One; 2019; 14(5):e0215248. PubMed ID: 31112536
[TBL] [Abstract][Full Text] [Related]
15. Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data.
Young JB; Gauthier-Loiselle M; Bailey RA; Manceur AM; Lefebvre P; Greenberg M; Lafeuille MH; Duh MS; Bookhart B; Wysham CH
Cardiovasc Diabetol; 2018 Aug; 17(1):118. PubMed ID: 30143045
[TBL] [Abstract][Full Text] [Related]
16. Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study.
Lee YC; Chang CH; Dong YH; Lin JW; Wu LC; Hwang JS; Chuang LM
Int J Cardiol; 2017 Feb; 228():1007-1014. PubMed ID: 27923207
[TBL] [Abstract][Full Text] [Related]
17. Prognostic indices among hypertensive heart failure patients in Nigeria: the roles of 24-hour Holter electrocardiography and 6-minute walk test.
Mene-Afejuku TO; Balogun MO; Akintomide AO; Adebayo RA
Vasc Health Risk Manag; 2017; 13():71-79. PubMed ID: 28280349
[TBL] [Abstract][Full Text] [Related]
18. Sitagliptin and risk of heart failure hospitalization in patients with type 2 diabetes on dialysis: A population-based cohort study.
Hung YC; Lin CC; Huang WL; Chang MP; Chen CC
Sci Rep; 2016 Jul; 6():30499. PubMed ID: 27460913
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal HbA1c trajectory modelling reveals the association of HbA1c and risk of hospitalization for heart failure for patients with type 2 diabetes mellitus.
Tee C; Xu H; Fu X; Cui D; Jafar TH; Bee YM
PLoS One; 2023; 18(1):e0275610. PubMed ID: 36662791
[TBL] [Abstract][Full Text] [Related]
20. Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2019 Apr; 12(4):299-308. PubMed ID: 30817235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
